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Abstract
Purpose To perform serum microRNA expression profiling to identify members of chromosome 19 miRNA cluster involved 
in preeclampsia development.
Methods Serum chromosome 19 miRNA cluster microRNA expression profiling was evaluated at 12, 16, and 20 gestational 
weeks and at the time of preeclampsia diagnosis, in women who developed preeclampsia (WWD-PE; n = 16) and controls 
(n = 18) using TaqMan low density array plates.
Results A total of 51 chromosome 19 microRNA cluster members were evaluated. The circulating hsa-miRs 512-3p, 518f-
3p, 520c-3p, and 520d-3p, were differentially expressed between groups (P < 0.05). Compared with controls, serum levels 
of hsa-miR-518f-3p at 20 GW were useful for identifying WWD-Mild-PE (P = 0.035) and WWD-Severe-PE (P = 0.007).
Conclusions Serum hsa-miRs 512-3p, 518f-3p, 520c-3p, and 520d-3p, are differentially expressed between WWD-PE and 
controls and their role in the development of preeclampsia should be investigated further.
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Introduction
Micro-RNAs (miRNA) are non-coding, single-stranded 
RNAs of 17–25 nucleotides in length that are highly con-
served during evolution and that function to negatively 
regulate gene expression by mechanisms such as transla-
tional repression, mRNA cleavage, and deadenylation [1–3]. 
Mechanistically, miRNAs exert their regulatory effects by 
binding to the complementary untranslated regions on their 
mRNA targets [2, 3]. One miRNA can regulate the mRNA 
degradation of many genes and thus has the ability to alter 
multiple signaling pathways and impact essential biologi-
cal processes such as human embryogenesis and placental Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00404-017-4611-6) contains 
supplementary material, which is available to authorized users.
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development [4, 5]. The placenta is a vital transient organ 
during pregnancy that is involved in the exchange of gases, 
nutrients, and waste products between the mother and the 
fetus. In a normal pregnancy, the placenta expresses ubiqui-
tous and specific miRNAs that participate in the regulation 
of trophoblast cell differentiation, proliferation, migration, 
invasion, angiogenesis, and apoptosis [6–9]. Numerous miR-
NAs expressed during pregnancy are clustered in chromo-
somal regions, may be controlled by the same promoters, 
may have similar seed regions and targets, and work syner-
gistically. The three most eminent clusters are the chromo-
some 19 miRNA cluster (C19MC), miR-371-3 cluster, which 
is also localized on chromosome 19, and the chromosome 
14 miRNA cluster (C14MC) [10]. The C19MC locus maps 
to chromosome 19q13.41, spans about 100 kb of genomic 
DNA and contains 46 pri-miRNA genes, yielding 59 mature 
miRNAs that are found exclusively in primates, attesting to 
their recent evolution [10, 11]. Although the expression of 
C19MC is mainly restricted to the reproductive system, the 
expression of hsa-miR-498 has been reported in fetal brain, 
and some C19MC members are highly expressed in human 
embryonic stem cells [10]. Based on microarray technol-
ogy, miRNAs within the C14MC, miR-371-3 cluster, and 
C19MC were found to be significantly upregulated in first 
trimester placentas [12]. Following on from this it was 
demonstrated that trophoblast and stromal cells of the villi 
release exosomes (small membrane microvesicles) into the 
maternal circulation [10, 13]. The exosomes miRNA com-
position strongly resembled that of the primary cells from 
which they were secreted. In both cases C19MC members 
accounted for the majority of mature miRNAs and six of 
them were among the top-ten exosomal miRNAs [13]. Based 
on these findings it has been assumed that these miRNAs 
play an important role in placental–maternal communica-
tion, possibly directing maternal adaptation to pregnancy 
[13, 14]. In pathological pregnancy conditions such as preec-
lampsia (PE; defined as hypertension and proteinuria after 
20 weeks of pregnancy), in which abnormal trophoblast 
invasion is the most important issue, recent studies suggest 
that deregulation of miRNA expression in placental tropho-
blasts may contribute to the development of the pathology 
[8, 13, 15, 16]. MiRNAs, including C19MC members have 
shown aberrant expression in case–control studies consist-
ing of individuals with PE and healthy pregnancy controls 
[8, 15, 17–20]. While studies initially focused on placental 
samples from term deliveries, pre-term circulatory samples 
from PE cases were soon revealed to also harbor detectable 
quantities of differentially expressed C19MC miRNAs [13, 
16]. Although the use of these circulating placental C19MC 
miRNAs as biomarkers for pregnancy-related disorders has 
been suggested, there is no conclusive evidence regard-
ing the presence of a differential expression profile of the 
C19MC associated with the development of PE. The aim of 
this study was to identify circulating members of C19MC 
at 12, 16, and 20 gestational weeks (GW) and at the time of 
PE diagnosis in serum samples from pregnant women who 
developed PE (WWD-PE) and from controls, to evaluate 
their association with the development of PE.
Methods
Patients and study design
We performed a nested cohort case–control study in which 
the participants were drawn from a cohort of 588 pregnant 
women who were followed from the first trimester to deliv-
ery as part of a screening study for adverse pregnancy out-
comes in the Centro de Salud Urbano de Zacatecas “José 
Castro Villagrana” and the Hospital de la Mujer Zacate-
cana, from Zacatecas’ Health Services, in Zacatecas, Mexico 
between November 2011 and January 2014. Sixteen women 
who developed PE during the follow-up period were selected 
and individually matched to 18 women in the cohort who 
had healthy pregnancies without complications (normoten-
sive controls). The criteria for PE diagnosis and its sever-
ity/onset sub-classifications were established as follows: PE 
was considered as severe if the patient had a blood pres-
sure ≥ 160 mmHg systolic or ≥ 110 mmHg diastolic on two 
occasions at least 6 h apart while the patient was at bed rest, 
and a proteinuria of 5 g or more in a 24-h urine specimen, 
or 3 + or greater in two random urine samples collected at 
least 4 h apart. Early PE was considered if present before 34 
GW and late PE as that occurring with more than 34 + 1 GW 
[21–23]. The study exclusion criteria included gestational 
hypertension, gestational diabetes mellitus, and underlying 
medical diseases such as chronic hypertension, diabetes mel-
litus type 2, hypo/hyperthyroidism, chronic renal disease, 
rheumatoid arthritis, and systemic lupus erythematosus. This 
protocol complied with the Declaration of Helsinki. The 
patients in the study provided written informed consent for 
their participation, and Institutional Review Board approvals 
were obtained from the participating institutions, as follows: 
Comité de Bioética del Área de Ciencias de la Salud-UAZ 
(ID numbers: ACS/UAZ. Ofc. Nos. 0072009, 0062010) and 
Comité de Enseñanza, Investigación, Capacitación y Ética 
from Hospital de la Mujer Zacatecana (ID numbers: HMZ-
520/281/11 and HMZ-5020/318/11).
Biological samples
All participants (initially normotensive pregnant women) 
provided peripheral blood at the 12th, 16th and/or 20th GW 
upon enrolling in the study. Patients who had a PE diagnosis 
during follow-up provided an additional blood sample at the 
time of diagnosis. Women with gestational ages that were 
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different from 12, 16, or 20 GW ranging between 13 and 19 
GW were also included in the study (although these par-
ticipants had lower sample numbers). Blood samples were 
collected in tubes without anticoagulant and centrifuged at 
2000 rpm for 10 min at room temperature. The serum was 
collected, aliquoted, and stored at − 80 °C until assayed. 
Blood samples with hemolytic processes or from patients 
with a urinary tract infection at the time of sampling were 
not considered for the study.
MiRNA isolation from serum samples
Before miRNA isolation, the serum samples were thawed on 
ice and centrifuged at 13,300 rpm for 5 min to remove any 
trace of cellular debris or sediment. Total RNA was isolated 
from 200 µl of serum using the miRNeasy Mini Kit (Qiagen 
Inc., Valencia, CA, USA) according to the manufacturer’s 
instructions and eluted in 50 μl of nuclease-free water. The 
RNA quality and concentration were assessed using a Nan-
oDrop 1000 spectrophotometer (NanoDrop Technologies 
Inc., USA).
Maternal serum miRNA profiling using a TaqMan 
low density array (TLDA)
A total of 99 miRNA samples from the 34 participants were 
included, with 24 from samples collected at 12 GW (6 from 
WWD-PE and 18 from controls), 28 at 16 GW (10 from 
WWD-PE and 18 from controls), 32 at 20 GW (14 from 
WWD-PE and 18 from controls), and the remaining 15 from 
the WWD-PE group at the time of PE diagnosis (Fig. 1). 
The C19MC miRNA expression was quantified for each of 
the 45 PE samples, while only 25 serum samples from five 
normotensive pregnant women were individually quantified 
at 12, 16, and 20 GW for the control group. One pooled 
sample from the 13 additional controls was also included for 
each time point (Fig. 1). Quantification of the serum levels 
of 51 C19MC members (Online Resource 1) was performed 
using Megaplex Pools from the TaqMan Human MicroRNA 
Array set v2.0 (Applied Biosystems, Foster City, CA, USA), 
according to the manufacturer’s instructions. cDNAs for the 
mature miRNAs were synthesized using 40–180 ng of total 
RNA from 99 serum samples. A 12-cycle pre-amplification 
round was included to enhance the ability to detect miRNAs 
with low expression. The cDNA synthesis and pre-amplifi-
cation steps were performed on a  Veriti® 96-Well Thermal 
Cycler (Applied Biosystems). Quantitative real-time poly-
merase chain (qRT-PCR) reactions were performed accord-
ing to the manufacturer’s instructions, replacing the sug-
gested pre-amplified product diluent (buffer TE 1×) with 
nuclease-free water. The qRT-PCR reactions were performed 
on an Applied Biosystems ViiA™ 7 Real-Time PCR System 
using the default cycling conditions. Quantification cycle 
(Cq) values were calculated using ViiA™ 7 Software, and 
the automatic baselines and thresholds were homogenized 
across multiple runs using Expression Suite software v1.0.3 
(Applied Biosystems). A sample was considered positive if 
the amplification signal occurred before the 37th Cq.
Data analysis
Comparisons of the risk factors and personal characteristics 
among the groups were performed using the Chi-squared 
test or Fisher’s exact test. Continuous variables were com-
pared between the groups using the Kruskal–Wallis one-way 
analysis of variance (ANOVA) on ranks coupled to Dunn’s 
method as a multiple comparison procedure. At each evalu-
ated pregnancy time point, the relative quantity (RQ) of cir-
culating miRNAs was determined from the qRT-PCR data 
using the global normalization method, the control group as 
a reference, and a confidence level of 95%. At the time of PE 
diagnosis, the comparison between the mild and severe PE 
groups was performed using the mild PE data as the refer-
ence. ΔCq values and standard errors were calculated for 
the data generated using ExpressionSuite software v1.0.3 
(Applied Biosystems).
Results
A total of 34 patients were selected for the study, including 
16 who developed PE during the follow-up and were among 
the women who developed PE (WWD-PE) (cases). The con-
trol group included 18 women with healthy pregnancies who 
Fig. 1  Summary of the serum samples included in the study. A total 
of 99 serum samples from the 34 participants were considered. In the 
controls one pooled sample was included for each stage of pregnancy. 
Each pooled sample (*) was prepared using 20 µl of serum from 13 
additional controls
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were individually paired with the WWD-PE patients based 
on parameters such as maternal age, nulliparity, personal and 
family histories of PE, and body mass index (Table 1). The 
mean maternal age was 23.5 years for the WWD-PE group 
and 23.4 years for the control group. The nulliparity variable 
was present in 37.5% of the WWD-PE patients and 50% of 
the controls (P = 0.699). No differences in other known PE 
risk factors or in clinical data were observed between the 
groups (Table 1 and Online Resource 2). At the time of PE 
diagnosis, the patients showed a mean systolic blood pres-
sure of 151.3 mm/Hg and a mean diastolic blood pressure of 
100 mm/Hg, and their urine protein values ranged between 
300 and 619.3 mg/dl. Of the cases, 25% of patients received 
a PE diagnosis before 34 GW (early PE), and the remaining 
75% had late-onset disease (range 34–37 GW). Thirty-one 
per cent of the cases were sub-classified as severe PE.
The expression of 51 C19MC members was evaluated in 
the study (Online Resource 1). Among the miRNAs evalu-
ated 10 miRNAs were detected (Cq < 37) in serum of the 
participants at 12 and 16 GW, while the amplification of 13 
C13MC members was detected at 20 GW (Table 2).
At 16 GW, the levels of circulating hsa-miR-520c-3p dif-
fered between the WWD-PE and control group (Table 2). 
At 20 GW, the serum concentration of hsa-miR-518f, hsa-
miR-512-3p, and hsa-miR-520d-3p was higher in WWD-
PE than that observed in pregnancies without complica-
tions (Table 2). The RQ values observed for the miRNAs 
at each time point were 2.4 for hsa-miR-520c-3p at 16 GW 
(P = 0.029), 3.7, 7.2, and 4.4 for hsa-miR-518f (P = 0.004), 
hsa-miR-512-3p (P  =  0.023), and hsa-miR-520d-3p 
(P = 0.024) at 20 GW, respectively. There were no differ-
ences in the serum C19MC signatures between study groups 
at 12 GW (P > 0.05).
To identify differences in circulating miRNA associ-
ated with the severity of clinical manifestations of PE, 
the participants were classified as women who developed 
mild PE (WWD-Mild-PE), women who developed severe 
PE (WWD-Severe-PE), and controls. Table 3 displays the 
members of C19MC with significant differences in serum 
Table 1  General characteristics 
of the study population
SD standard deviation
Characteristics WWD-PE (n = 16) Control (n = 18) P value
Maternal age (mean ± SD) 23.5 ± 5.1 23.4 ± 5.8 0.913
Body mass index (mean ± SD) 28.1 ± 5.5 27.2 ± 4.9 0.639
Number of pregnancies (median, range) 2 (1–5) 1 (1–4) 0.387
Nulliparous, n (%) 6 (37.5) 9 (50.0) 0.699
Personal history of PE, n (%) 1 (6.3) 1 (5.5) 1.0
Family history of PE, n (%) 1 (6.3) 1 (5.5) 1.0
Family history of hypertension, n (%) 13 (81.2) 13 (72.2) 1.0
Family history of diabetes mellitus type II, n (%) 8 (50) 13 (72.2) 0.176
Smoking during pregnancy, n (%) 0 (0.0) 0 (0.0) 1.0
Table 2  Serum expression levels of members of C19MC at the preg-
nancy time points evaluated
Significant P values are highlighted in bold
RQ relative quantification, GW gestation week
Time Target name RQ RQ min RQ max P value
12 GW hsa-miR-520d-3p 2.6 1.110 6.018 0.260
hsa-miR-518f 2.5 0.543 11.821 0.309
hsa-miR-520a 3.2 0.509 20.726 0.318
hsa-miR-518b 0.0 0.007 0.130 0.423
hsa-miR-520c-3p 0.8 0.114 6.270 0.425
hsa-miR-519a 0.2 0.008 4.412 0.524
hsa-miR-520f 0.5 0.000 725.01 0.575
hsa-miR-521 0.4 0.051 3.214 0.713
hsa-miR-523 4.3 2.093 8.672 0.742
hsa-miR-518a-3p 0.6 0.059 7.053 0.958
16 GW hsa-miR-520c-3p 2.4 1.206 4.673 0.029
hsa-miR-520d-3p 10.2 0.887 118.47 0.064
hsa-miR-520a 4.8 1.775 13.003 0.104
hsa-miR-518b 0.0 0.001 0.007 0.188
hsa-miR-523 0.4 0.101 1.346 0.626
hsa-miR-516-3p 0.5 0.186 1.550 0.652
hsa-miR-515-3p 0.5 0.046 5.130 0.668
hsa-miR-518a-3p 0.7 0.097 5.666 0.699
hsa-miR-518d 0.6 0.017 17.751 0.788
hsa-miR-518f 1.0 0.421 2.220 0.920
20 GW hsa-miR-518f 3.7 1.566 8.834 0.004
hsa-miR-512-3p 7.2 1.671 31.23 0.023
hsa-miR-520d-3p 4.4 2.175 9.088 0.024
hsa-miR-517a 1.2 0.603 2.384 0.131
hsa-miR-516-3p 0.3 0.189 0.600 0.151
hsa-miR-520c-3p 1.9 1.050 3.278 0.186
hsa-miR-515-3p 0.3 0.057 1.576 0.212
hsa-miR-519a 3.6 1.004 12.703 0.271
hsa-miR-518b 16.8 1.012 277.79 0.350
hsa-miR-520a 1.4 0.638 3.077 0.384
hsa-miR-521 1.0 0.372 2.581 0.760
hsa-miR-523 2.0 0.743 5.294 0.816
hsa-miR-518a-3p 0.6 0.151 2.065 0.950
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levels between study groups. Using the PE severity criteria 
as a classifier (see “Methods” for details), at 16 GW, the 
hsa-miR-520d-3p was differentially expressed between the 
WWD-Mild-PE and the control group (RQ 92.2, P = 0.04). 
At 20 GW, the level of hsa-miR-518f varied according PE 
severity, the highest RQ differences being between the 
WWD-Severe-PE and controls (RQ 6.43, P = 0.007).
At the time of PE diagnosis and considering the WWD-
Mild-PE group as a reference, the expression of the 51 
circulating miRNAs evaluated did not differ between the 
WWD-Mild-PE and WWD-Severe-PE groups (P > 0.05; 
data not shown).
Discussion
Members of the C19MC are highly enriched in the placenta, 
particularly in term trophoblast cells where they account for 
a significant proportion of cellular miRNA content and dem-
onstrate increased expression from the first to third trimester 
[13, 24, 25]. Because increased expression is mirrored in 
the maternal circulation and C19MC miRNAs comprise the 
majority of exosomal miRNAs, it is recognized that C19MC 
play an important role in the physiology of a normal preg-
nancy and therefore their deregulation may be used as a 
biomarker for pregnancy-related disorders including PE. 
Accordingly, in this study, we performed serum miRNA 
expression profiling to identify C19MC members involved 
in the development of PE. The circulating miRNA expres-
sion profile was evaluated at 12, 16, 20 GW, and at the time 
of PE diagnosis. Our results showed the differential expres-
sion of four members of the C19MC cluster between the 
WWD-PE and healthy pregnant women: one at 16 GW (hsa-
miR-520c-3p) and the remaining three at 20 GW (hsa-miRs 
518f-3p, 512-3p, and 520d-3p). A dynamic determination 
of the circulating C19MC expression profiles at different 
time points in early pregnancy has not yet been performed; 
however, using a transversal nested case–control study, 
Hromadnikova et al. compared pregnant women enrolled 
at 10–13 GW to evaluate risk for PE development based on 
six serum C19MC members. Circulating miR-517-5p, miR-
518b, and miR-520h were up-regulated in patients destined 
to develop PE [26]. Similarly, to identify circulating miRNA 
signatures associated with PE development, Ura et al. ana-
lyzed 754 miRNAs in serum samples obtained at 12–14 GW 
from pregnant women who later developed severe PE and 
controls [20]. Their results showed up-regulation of miR-
520a and miR-518b in women who developed severe PE. 
Although our study is not entirely comparable with these 
previous reports, and the miR-517-5p, and miR-518b expres-
sion was detected at the three time points evaluated, there 
were no significant differences between study groups. The 
“apparent” dissimilarities between studies may be explained 
in part by the stage of pregnancy at which the miRNA lev-
els were quantified (study design), and the differences in 
the PE stratification criteria used in the studies [20, 27]; 
more specifically in our study the time in pregnancy at which 
the circulating CM19C miRNA levels were evaluated was 
very strict and only women with the correct GW (12, 16 
or 20 GW) were included. Accordingly, we consider that 
there are specific serum miRNA signatures according to the 
gestational age of the participants and that this should be 
considered in future studies focused on validating circulat-
ing miRNA associated with PE development. In our study, 
at 20 GW and according to PE severity, the serum levels 
of hsa-miR-518f were useful to separately identify WPD-
Mild-PE, WPD-Severe-PE, and controls, demonstrating the 
differential modulation of miRNAs closely associated with 
miR-518 in early pregnancy, according to the current PE 
stratification criteria.
The presence of specific members of the C19MC in the 
maternal circulation has been associated with existing PE. 
At least 11 independent studies have discovered members 
of the C19MC to be among the most represented across PE 
case–control studies [25]. The most frequently cited C19MC 
members (and their specific variants) that are differentially 
expressed in PE are miR-518 (b/c/e/f), -517 (a/b/c/*), -519 
(a, b-3p, d, e, e*), and -520 (a, a-3p, c-3p, f, g, h) [25, 28]. 
In our study, no blood sample was taken from healthy preg-
nancies (paired with the PE cases) at the time of PE diag-
nosis, and therefore no comparison of circulating C19MC 
signatures between PE and controls was possible. Although 
the absence of a control group at the time of PE diagnosis 
was a disadvantage of the study, there were no differences 
in serum C19MC miRNAs between women diagnosed with 
mild-PE and severe-PE. However, it is important to mention 
Table 3  Members of C19MC 
differentially expressed between 
healthy pregnancies and 
WWD-PE, classified as mild or 
severe PE
Data were calculated using the control group as the reference
Target Regulation group GW RQ RQ min RQ max P value
hsa-miR-520d-3p Mild-PE 16 92.2 35.9 236.6 0.040
hsa-miR-518f Severe-PE 20 6.43 4.05 10.22 0.007
hsa-miR-517a Severe-PE 20 2.12 1.31 3.43 0.027
hsa-miR-518f Mild-PE 20 5.34 1.96 14.58 0.035
hsa-miR-520d-3p Mild-PE 20 6.37 1.66 24.49 0.044
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that these results should be considered carefully because 
the mild/severe PE cases were not paired according to risk 
factors and this may have introduced some bias in the statis-
tical analysis. Finally, some study limitations must be high-
lighted: the number of women who developed PE and who 
were available for the study was low and therefore validation 
of the miRNAs that differed between study groups is needed 
in an independent cohort. Similarly, the determination of 
parameters to evaluate the diagnostic test (cutoffs, predictive 
values, sensitivity, specificity, etc.) was not considered due 
to the low number of participants at each stage of pregnancy 
evaluated.
In summary, to the best of our knowledge, this study is the 
first to analyze the signatures of C19MC circulating miR-
NAs at four pregnancy time points in order to assess their 
association with the development and severity of PE. Our 
results provide evidence of the early differential modulation 
of the C19MC cluster in WWD-PE. This knowledge provides 
a basis for understanding the complex etiopathogenesis of 
PE and for developing early screening tests for the disease.
Conclusion
Serum levels of hsa-miRs 520c-3p at 16 GW, and the circu-
lating levels of hsa-miR-512-3p, 518f-3p, and 520d-3p at 20 
GW, were differentially expressed between WWD-PE and 
controls. The serum levels of hsa-miR-518f-3p at 20 GW 
were useful to identify WWD-Mild-PE, WWD-Severe-PE, 
and controls. Our results support the differential modulation 
of the C19MC cluster during early pregnancy in WWD-PE 
and thus their participation in the development of should be 
considered.
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